Gilead Sciences exercised its option license a Kymera Therapeutics’ protein-degrading drug designed to eliminate the cancer-driving protein CDK2. Meanwhile, Roche’s new partnership with C4 Therapeutics is focused on developing degrader antibody drug conjugates for undisclosed cancer targets.
The post Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines appeared first on MedCity News.
